Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
Date:6/2/2008

MISSISSAUGA, June 2 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that updated preliminary trial results, including survival, response rate and overall safety data, from its escalating dose trial of nimotuzumab were presented in a poster presentation on June 1st, 2008 at the Annual Meeting of the American Society of Clinical Oncology (ASCO). The phase I trial is evaluating nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, in combination with external radiotherapy in palliative treatment of patients diagnosed with stage IIb, III or IV non-small cell lung cancer (NSCLC) ineligible for chemotherapy-containing regimens.

"The median survival of 60 weeks in the palliative setting reported in this trial compares favorably with other recent trials in the same scenario, and suggests that the combination of nimotuzumab with radiation has the potential to provide a survival advantage to patients over radiation alone in the curative setting, the only alternative available to patients who are ineligible for, or unable to tolerate, chemotherapy-containing regimens," said David Allan, Chairman and CEO of YM BioSciences. "There is a significant subset of patients whose overall condition does not permit administration of chemotherapy in a combined-modality treatment to enhance their curative prospects."

Substantial radiological responses and meaningful clinical responses were seen in patients treated with the combination of nimotuzumab and radiation in each dosing cohort. This included an 89% Disease Control Rate of which 50% were Partial Responses. Eleven of the 18 patients were Stage IV, five were stage IIIb and two were Stage IIIa. No Stage II patients were enrolled. Patients were treated for eight weeks and then every two weeks until progression. Continue
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... focused on advanced wound care, announces that AMNIOEXCEL® ... have been added to the Premier, Inc. Regenerative ... opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product lines, ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... DALLAS, February 1, 2012 The report ... -   Global Trends, Opportunities & Forecasts (2011   - ... and studies the major market drivers, restraints, and opportunities in ... Browse market data tables and in-depth TOC ...
... 2012 New Report Added in ... Global Markets The report provides ... DDS and future opportunities (2011-2021).  Persons with a financial ... to learn how advances in nanotechnology research and development ...
... in Dayton, Ohio, has experimentally confirmed a theory by ... of interesting properties about nanotube growth: That the chirality ... and that armchair nanotubes should grow the fastest. ... the mysteries inherent in what Yakobson calls the "DNA ...
Cached Biology Technology:MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016 2MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016 3ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 2ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 3ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 4Rice professor's nanotube theory confirmed 2Rice professor's nanotube theory confirmed 3
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... $15,000 in a national competition for adapting a traditional ... villagers can use to make paper for their children,s ... of a machine to convert farm waste to paper, ... Houston during a ceremony honoring top submissions in the ...
... (11/12/2012) If you,ve eaten fish, gone for a boat ride or ... is a valuable commodity. But just how valuable? That,s always been ... the worth of clean water against societal needs that compromise it, ... Now, however, their ability to do so has been greatly enhanced ...
... have estimated that there are 1.7 million species of ... continue to be discovered. Unfortunately, as new species are ... decrease in biodiversity. The more diversity there is in ... Hence, biodiversity is key to ecosystem resilience. Disease, ...
Cached Biology News:Plan to turn farm waste into paper earns students $15,000 2Study offers new tool for incorporating water impacts into policy decisions 2Persistence or extinction: Through a mathematical lens 2Persistence or extinction: Through a mathematical lens 3
... Arginine methylation is an irreversible post ... linked to protein activity. At least three ... in mammalian cells. These enzymes have been ... methylation of key proteins in several fundamental ...
... Biotinylation Kit, Plasmid is designed for use with ... kits. (Cat. No. 3 186 148, 3 186 ... for the easy introduction of a C- or ... be enzymatically mono-biotinylated by E. coli biotin protein ...
... the major proteolytic system in the ... catalyzes the selective degradation of short-lived ... of proteins with abnormal conformation (Hershko ... critical protease in this pathway is ...
... sensitive, fast and specific detection of chromosomal ... Short hybridisation time ( ... Multiplex capability Available with different ... Probes available with different labels. Related ...
Biology Products: